New crystal form and use of nitrogenous tricyclic compound

Abstract

A new crystal form and use of a nitrogenous tricyclic compound in the field of drugs. Specifically, a new crystal form of 2-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-10H-spiro[benzo[6,7]oxepino[3,2-b]pyridine-11,1′-cyclopropane]-7-carboxylic acid, and the new crystal form is a crystal form I. A pharmaceutical composition including the crystal form I, and the use of the crystal form I or the pharmaceutical composition in preparation of a drug for preventing, treating, or relieving an FXR-mediated disease of a patient.

1 . A crystal form of a compound having Formula (I), which is crystal form I, 
       
         
           
           
               
               
           
         
       
       wherein the crystal form I exhibits the following characteristic X-ray powder diffraction peaks expressed as 2θ at 4.43°±0.2°, 11.59°±0.2°, 19.54°±0.2°, 21.65°±0.2°, 24.25°±0.2°, 25.59°±0.2°. 
     
     
         2 . The crystal form according to  claim 1 , wherein the crystal form I exhibits the following characteristic X-ray powder diffraction peaks expressed as 2θ at 4.43°±0.2°, 11.59°±0.2°, 13.56°±0.2°, 19.54°±0.2°, 19.86°±0.2°, 20.89°±0.2°, 21.65°±0.2°, 23.39°±0.2°, 24.25°±0.2°, 25.59°±0.2°, 28.13°±0.2°. 
     
     
         3 . The crystal form according to  claim 1, claim 1 or 2 , wherein the crystal form I exhibits the following characteristic X-ray powder diffraction peaks expressed as 20 at 4.43°±0.2°, 8.05°±0.2°, 8.83°±0.2°, 9.42°±0.2°, 11.59°±0.2°, 12.96°±0.2°, 13.56°±0.2°, 14.06°±0.2°, 14.70°±0.2°, 15.59°±0.2°, 17.06°±0.2°, 17.32°±0.2°, 17.82°±0.2°, 18.52°±0.2°, 18.93°±0.2°, 19.54°±0.2°, 19.86°±0.2°, 20.30°±0.2°, 20.89°±0.2°, 21.65°±0.2°, 22.18°±0.2°, 22.60°±0.2°, 23.39°±0.2°, 24.25°±0.2°, 24.79°±0.2°, 25.59°±0.2°, 25.99°±0.2°, 26.69°±0.2°, 27.26°±0.2°, 28.13°±0.2°, 28.56°±0.2°, 29.77°±0.2°, 30.41°±0.2°, 30.75°±0.2°, 31.23°±0.2°, 33.08°±0.2°. 
     
     
         4 . The crystal form according to  claim 1 , wherein the crystal form I has an X-ray powder diffraction pattern substantially as shown in  FIG.  1   . 
     
     
         5 . The crystal form according to  claim 1 , wherein the crystal form I has a differential scanning calorimetry thermogram comprising endothermic peaks at 177.02° C.±3° C. and 195.73° C.±3° C. 
     
     
         6 . The crystal form according to  claim 1 , wherein the crystal form I has a differential scanning calorimetry thermogram substantially as shown in  FIG.  2   . 
     
     
         7 . A pharmaceutical composition comprising the crystal form of  claim 1 , and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant or a combination thereof. 
     
     
         8 . A method for preventing, treating or lessening a disease mediated by FXR in a patient, comprising administering to the patient a pharmaceutically acceptable effective amount of the crystal form according to  claim 1 . 
     
     
         9 . The method according to  claim 8 , wherein the disease mediated by FXR is cardiovascular and cerebrovascular disease, a disease related to dyslipidemia, metabolic syndrome, hyperproliferative disease, fibrosis, inflammatory disease or a disease related to liver and gallbladder. 
     
     
         10 . The method according to  claim 9 , wherein the cardiovascular and cerebrovascular disease is atherosclerosis, acute myocardial infarction, venous occlusive disease, portal hypertension, pulmonary hypertension, heart failure, peripheral arterial occlusive disease, sexual dysfunction, stroke or thrombosis;
 wherein the metabolic syndrome is insulin resistance, hyperglycemia, hyperinsulinemia, elevated levels of fatty acid or glycerol in the blood, hyperlipidemia, obesity, hypertriglyceridemia, hypercholesterolemia, syndrome X, diabetic complications, atherosclerosis, hypertension, acute anemia, neutropenia, dyslipidemia, type II diabetes mellitus, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, dyslipidemia, or comorbidities of diabetes and abnormally high body mass index;   wherein the hyperproliferative disease is hepatocellular carcinoma, colonic adenocarcinoma, polyposis, colonic adenocarcinoma, breast cancer, membrane adenocarcinoma, Barrett's esophagus cancer, or other forms of gastrointestinal or liver neoplastic diseases;   wherein the fibrosis, inflammatory disease or disease related to liver and gallbladder is non-alcoholic fatty liver, non-alcoholic steatohepatitis, cholestasis, liver fibrosis, primary biliary cirrhosis, primary sclerosing cholangitis, progressive familial intrahepatic cholestasis, cystic fibrosis, drug-induced bile duct damage, gallstones, liver cirrhosis, hepatitis B, sebaceous gland disease, alcohol-induced liver cirrhosis, bile duct obstruction, gallstone disease, colitis, neonatal Jaundice, nuclear jaundice, or overgrowth of intestinal bacteria.   
     
     
         11 . A method for preventing, treating or lessening a disease mediated by FXR in a patient, comprising administering to the patient a pharmaceutically acceptable effective amount of the pharmaceutical composition of the invention according to  claim 7 . 
     
     
         12 . The method according to  claim 11 , wherein the disease mediated by FXR is cardiovascular and cerebrovascular disease, a disease related to dyslipidemia, metabolic syndrome, hyperproliferative disease, fibrosis, inflammatory disease or a disease related to liver and gallbladder. 
     
     
         13 . The method according to  claim 12 , wherein the cardiovascular and cerebrovascular disease is atherosclerosis, acute myocardial infarction, venous occlusive disease, portal hypertension, pulmonary hypertension, heart failure, peripheral arterial occlusive disease, sexual dysfunction, stroke or thrombosis;
 wherein the metabolic syndrome is insulin resistance, hyperglycemia, hyperinsulinemia, elevated levels of fatty acid or glycerol in the blood, hyperlipidemia, obesity, hypertriglyceridemia, hypercholesterolemia, syndrome X, diabetic complications, atherosclerosis, hypertension, acute anemia, neutropenia, dyslipidemia, type II diabetes mellitus, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, dyslipidemia, or comorbidities of diabetes and abnormally high body mass index;   wherein the hyperproliferative disease is hepatocellular carcinoma, colonic adenocarcinoma, polyposis, colonic adenocarcinoma, breast cancer, membrane adenocarcinoma, Barrett's esophagus cancer, or other forms of gastrointestinal or liver neoplastic diseases;   wherein the fibrosis, inflammatory disease or disease related to liver and gallbladder is non-alcoholic fatty liver, non-alcoholic steatohepatitis, cholestasis, liver fibrosis, primary biliary cirrhosis, primary sclerosing cholangitis, progressive familial intrahepatic cholestasis, cystic fibrosis, drug-induced bile duct damage, gallstones, liver cirrhosis, hepatitis B, sebaceous gland disease, alcohol-induced liver cirrhosis, bile duct obstruction, gallstone disease, colitis, neonatal Jaundice, nuclear jaundice, or overgrowth of intestinal bacteria.